1

Submitted by: Group-13

Sr. Nb. Name ID
01 Md. Sabbir Mia 86
02 Md. Imran Hasan Bhuiyan 88
03 Md. Rejaul Alam 92
04 Md. Alamin 124
05 Nurul Islam 127

Submitted to
Md. Nazmus Sakib
Lecturer
Advanced Accounting (MGT-203)
Department of Management
University of Dhaka

Date of Submission
10th December, 2023

2
Table of Contents:

Tittle Fly ................................................................................................................ 1

Tittle Page ............................................................................................................. 2
Executive Summary: ............................................................................................. 4
Introduction: .......................................................................................................... 5
Objectives:............................................................................................................. 6
Company Overview: ............................................................................................. 7
Methodology: ........................................................................................................ 9
Analysis and Findings: ........................................................................................ 10
i.Statement of Profit or Loss and Other Comprehensive Income .................... 10
ii.Statement of Financial Position .................................................................... 15
iii.Retained Earnings statement ....................................................................... 17
iv.Key and findings: ......................................................................................... 18
Attachments: ....................................................................................................... 19
References: .......................................................................................................... 19

3
Executive Summary:

The term paper mainly focuses on "The Beximco Pharmaceuticals Company Ltd.
and analysis of its financial statements. Where we calculated financial statement,
income statement, cash flow and retained earnings.

We attempt to write about our selected company Baximco Pharmaceuticals Limited.

and accounting related data analysis the process how they calculate the financial
statement and what is the financial policy of Beximco Pharmaceuticals Limited.

Beximco Pharmaceuticals Limited. is one of the leading pharmaceuticals company in

Bangladesh. yeah they have other said to also, but in this report we only follow
through the Baximco Pharmaceuticals Limited. the follows the rules of IFRS to
calculate and making their financial statement. we need to clear one think is that our
recharge is based on only the financial year of June 2021 to July 2022.

4
Introduction:

We are presenting Beximco Pharmaceuticals Limited company for the assignment of

advanced accounting course. At first we need to know about Beximco before
Knowing about Beximco Pharmaceuticals Limited.

Beximco Pharmaceuticals Limited is a leading manufacturer and exporter of

medicines in Bangladesh. Incorporated in 1976, the Company started its operation by
importing products from Bayer, Germany and Upjohn, USA and selling them in the
local market. In 1980, Beximco Pharma began manufacturing of these products under
licensing arrangement and the company launched its own formulation brands in 1983.
From that humble beginning, Beximco Pharma has grown from strength to strength.
Today, it has emerged as a global generic pharma company in the region. The
Company’s manufacturing facilities have been accredited by the leading global
regulatory authorities, and medicines manufactured by the Company are now being
exported to more than 50 countries including the highly regulated markets of USA,
Europe, Canada and Australia. Beximco has won the National Export (Gold) trophy
for 5 times. It remains the only Company in the country to win the highly prestigious
SCRIP Award as the “Best Pharma Company in an Emerging Market” and also won
CPHI Pharma Awards 2020 for “Innovation in Response to COVID-19.” It also has
the unique distinction as the on.

5
Objectives:

There are some important objectives of our term paper regarding accounting
information of Beximco Pharmaceuticals Limited.

 To introduce the information as regards accounting of Beximco

Pharmaceuticals Limited.
 To incorporate knowledge of accounting information of Beximco
Pharmaceuticals Limited.
 To introduce financial statements of Beximco Pharmaceuticals Limited.
 To know the software use of Beximco Pharmaceuticals Limited.
 To know the challenge of Beximco Pharmaceuticals Limited.

6
Company Overview:

Today the BEXIMCO Group ("BEXIMCO" or the "Group") is the largest private
sector group in Bangladesh. BEXIMCO was founded in the 1970's by two brothers -
Ahmed Sohail Fasihur Rahman and Salman Fazlur Rahman. Since the early days, the
Group has evolved from being primarily a commodities trading company to a leading,
diversified group with a presence in industry sectors that account for nearly 75% of
Bangladesh's GDP. BEXIMCO's corporate mission is "Taking Bangladesh to the
world

Bangladesh Export Import Company Limited, commonly known by its trade name
BEXIMCO, is a Bangladeshi multinational conglomerate holding company,
headquartered in Dhaka, Bangladesh. It was founded in the early 1970s.
BEXIMCO is Bangladesh's largest conglomerate, with the largest market
capitalisation on the country's stock market. BEXIMCO currently has operations and
investments across a wide range of industries including textiles, pharmaceuticals,
PPE, ceramics, real estate development, construction, trading, marine food,
information and communication technologies, media, DTH, financial services, and
energy. BEXIMCO's subsidiaries export products to 55 countries worldwide. It has
retail outlets in South Asia and Eastern Europe. It is one of the largest private sector
employers in Bangladesh with over 70,000 people worldwide.
BEXIMCO operates one of the largest integrated textile production businesses in
Asia. Its main manufacturing base is the BEXIMCO Industrial Park in Gazipur,
Bangladesh. Beximco Pharma, the group's pharmaceutical producer, was the first
Bangladeshi company to be listed on the London Stock Exchange.

7
The conglomerate compromises four public traded and eight privately held
companies.

01.Bangladesh Export Import Co. Ltd. (public)

02.Beximco Pharma (public)
03.Beximco Computers Ltd.
04.Beximco Engineering Ltd.
05.Beximco Aviation Limited
06.Beximco Petroleum Ltd.
07.Beximco Power Company Ltd.
08.Beximco Synthetics Ltd. (public)
09.Giga Tech Ltd.
10.Independent Television
11.Shinepukur Ceramics (public)
12.IFIC Bank Limited

Among those listed company of beximco we choosed Beximco pharmaceuticals

limited. Most of us are infected with diseases. Medicines are one of our daily
necessities. Beximco Pharmaceuticals is one of the best companies in Bangladesh for
these essential drugs. And The head office of Beximco pharmaceuticals limited is near
our campus at Rd no.01, Dhanmondi. During the strike moment, it was easy to go for
us. Thats why we select this company for our assignment.

Beximco Pharmaceuticals Ltd also known as Beximco Pharma, is a pharmaceutical

company in Bangladesh. It is a part of Bangladesh Export Import Company Limited
(BEXIMCO). Nazmul Hassan Papon is managing director of Beximco
Pharmaceuticals Limited

8
Methodology:

1.1 Source of data: The data has been collected from secondary source as well as
primary source. Those include:
1.website
2.Articles
3. questionnaire
1.2 Scope of the Report:
While completing the report we've had a lot of scopes of gathering knowledge of real
business world and the wide horizon of business, although the report is only
concerned about the Beximco Pharmaceuticals Limited. We have collected their
information from the internet and its head office. We got almost all the information
we needed because the website of the company is very much updated and resourceful.
We knew about their mission, vision, products, area of operation, accounting system,
managerial and organizational structure etc. We are really grateful to our course
teachers for assigning us such an interesting and knowledgeable topic.
1.3 Limitation of the report:
While preparing this report, we have faced some problems. The main problem was to
co- ordination all the group members. Moreover, during data collection we faced
several problems.

⚫ Due to limited access of the data, this study may not be perfect to the scent percent.
Lack of enough experience in analyzing of data.
Due to inadequate information, in-depth analysis could not be done in the report.

9
 Analysis and Findings:

Beximco Pharmaceuticals Limited

Statement of Profit or Loss and Other Comprehensive Income
For the Year ended June 30, 2022
Particulars Notes TK TK
Net Sales Revenue 1 30,220,731,648
(-) Cost of Goods Sold (16,507,965,726)
Gross Profit 13,712,765,922
(-) Operating Expenses
Administrative Expenses 2(A) (881,516,329)
Selling and Marketing Expenses 2(B) (6,237,421,187)
Total operating expenses (7,118,937,516)
Profit from Operations 6,593,828,406
(+) Others Income 3 1,456,174,446
(-) Finance Cost 4 (976,632,093)
Profit Before Contribution to WPPF & 7,073,370,759
Welfare Funds

(336,827,179)
Contribution to WPPF & Welfare Funds

Profit Before Tax Income 6,736,543,580

Tax Expenses
Current Tax 5
(1,018,534,760)
Deferred Tax (556,665,177)
Net Tax (1,575,199,937)
Profit after Tax 5,161,343,643
(+) Other Comprehensive
6
Income 6,764,517

Total Comprehensive Income

5,168,108,160

Earnings Per Share (EPS) 7

11.57

10
Note: 1
Net Sales Revenue:

Domestic Sales 27,553,566,457

Export Sales 2,667,165,191
30,220,731,648
Note: 2 (A)
Administrative Expenses:

Salary & Allowances 471,393,956

Rent 26,468,207
Repairs and Maintenance 71,324,489
Registration & Renewals 5,265,798
Travelling & Conveyance 27,053,843
Entertainment 8,227,022
Printing & Stationery 4,404,963
Audit Fee 2,100,000
Telephone, Cellphone, Internet 6,309,245
Electricity, Gas & Water 22,413,302
Legal & Consultancy 25,736,959
Business Acquisition Cost 57,302,224
Company Secretarial, Regulatory Fee 41,725,709
Municipal Tax & Land Revenue 1,951,304
Training & Conference 4,598,977
Depreciation 44,022,872
Meeting Fee 2,203,200
Security Expenses 18,858,186

Other Expenses 40,156,073

881,516,329

11
Note: 2 (B)
Selling, Marketing and Distribution Expenses

Software & Licenses 27,436,672

Electricity, Gas & Water 20,261,165
Market Research & New Products 66,845,465
Training & Conference 112,510,501
Insurance Premium 31,351,563
Sample Expense 376,783,020
Advertisement 835,673
Field Operation 45,784,860
Events, Programs & Campaign 261,461,875
Brand Development 141,621,329
CSR Expenses 12,646,614
Sales Promotion Expenses 153,209,813
Books, Journal and Periodicals 5,639,310
Salesforce Logistics 25,219,903
Clinical Studies and Research 6,946,764
Pharmacovigilance 20,146,600
Literature and News Letter 234,061,330
Registration & Renewals 135,590,529
Export Insurance Expenses 208,027,169
Distribution Commission 527,996,777
Delivery Expense 448,553,137
Depreciation & Amortization 145,913,133
Security Expenses 19,313,099
Bad Debts 2,875,000
Other Expenses 9,436,938
6,237,421,187

12
Note: 3
Other Income

Interest Income 699,570

Dividend 71,517,955
Royalty 149,208,374
Distribution Commission Income 222,559,867
Cash Incentive on Export 261,154,366
Exchange Rate Fluctuation Gain/Loss 49,926,288
Vaccine Distribution Fee 619,259,365
Forfeited PF refund 159,301
Technical know-how fee 79,552,390
Profit/(Loss) on Sale of Fixed Assets (Note 41) 2,136,970
1,456,174,446

Note: 4
Finance Cost:
Interest on Bank Borrowings 662,823,473
Interest on Lease Finance 42,741,408
Interest on Loan from PF, WPPF & Welfare Fund 199,775,709
Bank and Other Charges 71,291,503
976,632,093

a. Export Profits are subject to 12% Tax rate

b. 10% Tax deductible at source on the cash incentives are treated as
final tax liability on such income as per the Income Tax regulations.
c. Dividend Income is taxable @ 20%
Note: 5
Tax Rate is 23.38%

13
Note: 6
Other Comprehensive Income - Unrealized Gain/(Loss):
Fair Value Gain/(Loss) on Investment in Listed Shares 6,764,517

Note: 7
Earnings Per Share (EPS):
Weighted average number of shares outstanding during the year 446,112,089
Earnings Per Share (EPS) 11.57

14
 Beximco Pharmaceuticals Limited
Statement of Financial Position
As at June 30, 2022

Account Title Amount in Taka Amount in Taka

Assets
Non-current asset
Property, plant, equipment-carrying value 35,879,081,450
Right-of-use Assets 565,076,673
Intangible Assets 752,955,380
Investment in subsidiaries 6,911,821,604
Investments in associates 29,325,720
Others investment 23,356,899

Total non-current assets 44,161,617,726

Current asset 8,802,040,026

Inventories 664,709,483
Spare and supplies 2,739,772,443
Account receivable 2,510,263,322
Loan advance and deposit 816,224,089
Cash and cash equivalents
15,533,009,363

59,694,627,089

15
 TOTAL
ASSETS
Equity and Liabilities
Shareholder equity 4,461,120,890
Issued share capital 5,269,474,690
Share premium 1,689,636,958
Excess of issue price face value of GDRs 294,950,950
Capital reserve on merger 1,116,896,688
Revaluation surplus 20,531,723
Unrealized gain/loss 27,463,126,402
Retained earning 40,315,738,301

Total shareholder equity 3,401,537,415

Non-current liabilities 2,482,846,648
Long term borrowing -net of current maturity 2,427,208,876
Liability for gratuity and WWPF and welfare funds 8,311,592,939
Deferred tax liability
Total non-current liabilities
Current liabilities and provisions 6,363,686,217
Short term borrowing 2,039,694,209
Long term borrowing -current maturity 1,908,464,970
Creditor and other payables 576,413,875
Accrued expenses 87,370,715
Dividend payable 91,665,863
Income tax payable
Total current liabilities 11,067,295,849
TOTAL EQUITY AND LIABILITIES 59,694,627,089

16
 Beximco Pharmaceuticals Limited
Retained Earnings statement
For the Year ended June 30, 2022
Particulars Taka Taka
Retained Earnings, July 01, 2021 24,179,782,862

Add.
Profit for the Year 5,123,136,712
Adjustment for Depreciation on Revalued
Assets 6,358,656
5,129,495,368

Less.
Cash Dividend (1,561,392,312)

27,747,885,918
Retained Earnings, June 30, 2022

17
Key and findings:
1.The company use reducing method for depreciation of tangible asset.
2. The company use straight line method for depreciation of intangible asset.
3.The company use oracle software for record and analysis the transaction.

18
Attachments:

References:

Ahmed, Kamal Uddin. (2023). Deputy General Manager. Accounting Information Metting. Dhaka:
Beximco Pharma.
Md. Mahfuz Sumon. (2023). SR. Manager, Accountants and Finance. Accounting Infoemation
Meeting . Dhaka: Beximco Pharma.
https://www.beximcopharma.com/. (2023). Dhaka.

19